Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 7/20 | 0.60 |
| ▸ | DRD4 | P21917 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997979 | 0.90 | SMO (0.60) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL10360539 | 0.86 | SMO (0.64) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL5228465 | 0.83 | SMO (0.46) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL5224916 | 0.83 | SMO (0.44) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL3322562 | 0.81 | SMO (0.58) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL2001554 | 0.80 | SMO (0.50) | SMODRD4DRD2DRD3ADRA1A | |
| SCHEMBL5223624 | 0.80 | SMO (0.41) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL2761237 | 0.79 | SMO (0.43) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL9961694 | 0.78 | SMO (0.58) | SMODRD4DRD2DRD3MAPT | |
| SCHEMBL9961704 | 0.78 | SMO (0.58) | SMODRD4DRD2DRD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960413-B2 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-1611094-B1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060276650-A1 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276650-A1 | Pyrazole compounds | HTR1D, HTR1A, HTR3A | SMO 3168/4885DRD4 119/4885DRD2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.